Ποια είναι η τιμή για Instem plc (INS)

Η τιμή για Instem plc (INS) είναι $10.38

Ποια είναι η κεφαλαιοποίηση αγοράς για Instem plc (INS)

Η κεφαλαιοποίηση αγοράς για Instem plc (INS) είναι $158.81M

Instem plc (INS) Τιμή και Κεφαλαιοποίηση Αγοράς

Established in 1969 and based in Stone, United Kingdom, Instem plc provides information technology applications to the global life sciences and healthcare sectors. The company's core mission is to equip organizations with robust solutions for data capture, management, and analysis, thereby facilitating informed, data-driven decision-making processes. Instem's extensive suite of offerings addresses diverse needs across research and development. For early-phase clinical trials, it offers ALPHADAS, an eSource system. Discovery research is supported by tools like BioRails for data management and Morphit for data visualization. The portfolio also includes computational toxicology products and services, alongside Provantis, a Windows-based system for non-clinical evaluation studies. Specialized solutions comprise Comet Assay IV, a live video imaging system for reproducible comet slide scoring, and Cyto Study Manager for cytology data acquisition and reporting. Furthermore, NOTOCORD-hem software platforms are available for acquiring, displaying, and analyzing physiological signals. A significant area of focus is regulatory information management. Instem provides Samarind RMS for managing medical product information and a comprehensive set of tools for the Standard for Exchange of Nonclinical Data (SEND). This includes the submit platform for creating and managing SEND datasets, SENDView for reviewing them, SEND Explorer for web-based access with optional data warehousing, and SENDTrial, a subscription-based web solution. Other offerings include Logbook, an information repository, and the Sorcerer Colony Counter for automatic plate counting. Beyond its software products, Instem delivers a broad range of services such as sales support, training, validation, consultancy, and cloud services, in addition to safety assessment and regulatory information management software. The company also develops, manufactures, and supplies both software and hardware specifically for in vitro study data collection and management, enabling intelligence extraction from R&D related healthcare data.

Η τιμή για INS	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$336,719 $158.81M	NVDA	$5.152T	+3,244,331.71%
$296,498 $158.81M	AAPL	$4.537T	+2,856,783.22%
$272,419 $158.81M	GOOG	$4.169T	+2,624,774.67%
$238,031 $158.81M	MSFT	$3.642T	+2,293,424.81%
$183,290 $158.81M	AMZN	$2.805T	+1,765,973.34%

Η τιμή για INS

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$336,719 $158.81M